Quarterly Report · 10-Q

Medicus Pharma Ltd.

MDCXNASDAQEQUITYCurrent

Quarterly Report

Filed Nov 6, 2026Accepted Nov 6, 2026, 4:06 PM ESTCIK 1997296Accession 0001062993-26-005803

Company context

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Current securities

MDCXNASDAQ · EQUITY · Current MDCXWNASDAQ · WARRANT · Current

Recent company filings

Registered securities in this filing

MEDICUS PHARMA LTD. · 10-Q · Filed 2026-11-06

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common shares, no par value

Symbol: MDCX
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_20260101to20260930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember

Dimensions: us-gaap:StatementEquityComponentsAxis

Warrants

Symbol: MDCXW
Exchange: NASDAQ
Classification: WARRANT
Status: Current

Filing context

Context: C_20260101to20260930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember

Dimensions: us-gaap:StatementEquityComponentsAxis

Accession 000106299326005803 · 2 registered-security cover members

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.